Signify Premium Insight: Screening Marks the Next Step in Intelerad’s Grand Ambition
Published: September 2, 2022
Intelerad added another company to its growing portfolio in August, acquiring breast and lung screening specialist PenRad Technologies. The acquisition of the vendor, which provides software to enhance the efficiency of screening programmes, is the latest in a string of purchases including Ambra Health, Insignia and Lumedx among others.
The deal, which was of an undisclosed value, will bolster Intelerad’s offerings for mammography and lung workflow tools and analytics. Its three core products, PenRad for breast imaging, PenLung from lung screening, and PenTrac for patient tracking and reporting will, according to Intelerad, help radiologists using its enterprise imaging platform to optimise workflows and manage screening programmes more efficiently.
Read the full insight with a Signify Premium Insight – Medical Imaging subscriptionSign up for a free trial today.
Imaging IT – Market Intelligence ServiceOngoing series of reports, data and insights delivered over the year
Imaging IT – Market Intelligence Service
This Market Intelligence Service is an annual subscription that provides ongoing data, insights and analysis on the global opportunities for Imaging IT.
Find out more